Express Scripts/Medco's Broad Reach Could Reshape Specialty Benefit Dynamics
If it wins Federal Trade Commission approval, the proposed merger of Express Scripts Inc. and Medco Health Solutions Inc. would play out against a market driven in large part by high-priced specialty products and rampant genericization.
You may also be interested in...
The FTC voted in a split 3-1 vote to close its investigation and allow Express Scripts’ $29.1 billion acquisition of rival PBM Medco to proceed.
Express Scripts’ merger agreement with Medco to form a mega-pharmacy benefits manager may fit into the new realities of the post-health care reform world, but it was also likely hastened by contract losses at Medco.
New efforts by US payors suggest oncologics no longer enjoy the same protected reimbursement status they once did, potentially pulling the rug from under biopharma's hottest development, dealmaking, and revenue generating activities. To succeed in an increasingly competitive marketplace, biopharmas must adapt their strategies with an eye to reducing payors' overall costs.